Navigation Links
Lilly Presents Follow-Up Data on Semagacestat to Assist Future Alzheimer's Disease Research
Date:7/19/2011

INDIANAPOLIS, July 19, 2011 /PRNewswire/ -- Data were presented today from the first of two Phase III trials of semagacestat, including data from a 32 week follow-up period after dosing was halted in August 2010. Semagacestat is a gamma secretase inhibitor that had been studied as a potential treatment for Alzheimer's disease. Results shown today provided patient outcomes from the active treatment portion of the study and from a modified portion of the study conducted after dosing with semagacestat was stopped. Lilly presented the data during a plenary session at the Alzheimer's Association International Conference 2011 (AAIC 2011) in Paris, France.

The dosing in both semagacestat trials was halted in August 2010 because preliminary results from the two Phase III trials showed semagacestat did not slow Alzheimer's disease progression and was associated with worsening of clinical measures of cognition and the ability to perform activities of daily living. Lilly continued to gather data, including cognitive scores, for 32 weeks after dosing was stopped.

"When we made the decision to halt dosing in the trials, we committed to collecting this data in an effort to benefit future Alzheimer's research and to provide safety follow-up for the patients," said Eric Siemers, M.D., senior medical director for the Alzheimer's Disease Team at Eli Lilly and Company. "We have a great deal of appreciation and respect for the dedication of the patients and caregivers who remained committed to the semagacestat trials from the beginning until these follow-up data were collected. By obtaining this information, future research efforts can be guided much more effectively."  

The study data confirmed preliminary results that showed that during the period of dosing, patients receiving semagacestat declined at a greater rate than patients taking placebo. During the follow-up period after dosing was halted, the cognitive and functional deficits of the patients in
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Lilly and Argonne National Laboratory Announce $2 Million Upgrade to Lillys Beamline Capabilities
2. Lilly Donation to Patient Advocate Foundation Expands Services and Access for Patients With Most Common Form of Lung Cancer
3. Lilly CEO Says Biopharmaceuticals Should Be Included in Transatlantic Trade and Economic Discussions
4. Lilly CEO Calls for Improved Dialogue in Germany Between Industry and the Government and Health Care System
5. Lilly Quality Leader Walsh Appointed to Companys Executive Committee
6. Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations
7. Lilly Announces New Investment to Further Boost Its Biotechnology Capabilities
8. Lilly Declares Third-Quarter 2011 Dividend
9. Lilly for Better Healthâ„¢ Launches Enhanced Multi-Channel Patient Education Platform
10. Synthes and Lilly Sign Development and Collaboration Agreement
11. U.S. District Court Rules in Favor of Lilly in Amylin Litigation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... Burzynski Research Institute, Inc. (BRI) announced today ... given the company permission to conduct an open-label study ... months of age with a diffuse intrinsic brainstem glioma ... five treatment groups based on their age and whether ... The primary study endpoint is a decrease in the ...
(Date:10/22/2014)... , Oct. 22, 2014  Rescheduling of ... transformation in the pain market, according to a ... Inc., a firm providing market research and consultation ... Photo - http://photos.prnewswire.com/prnh/20141021/153440 ... change for hydrocodone combination products from Schedule III ...
(Date:10/22/2014)... Oct. 22, 2014   Reproductive Medicine Associates ... in the field of infertility, presents new clinical ... screening. The research abstract, released during the 70 ... (ASRM) meeting in Honolulu, Hawaii ... gene defect (SGD) pre-implantation genetic diagnosis (PGD). ...
Breaking Medicine Technology:Burzynski Research Institute, Inc. Announces FDA Permission to Launch a New Clinical Trial in Diffuse Intrinsic Brainstem Glioma 2Hydrocodone: Rescheduled, Repositioned & Reinvented 2Hydrocodone: Rescheduled, Repositioned & Reinvented 3New IVF Research Highlights Improved Genetic Screening Approach To Help Parents Have Healthier Babies 2New IVF Research Highlights Improved Genetic Screening Approach To Help Parents Have Healthier Babies 3
... UPI ), a medical device company that develops, ... announced today that David Kaysen, President and CEO, and Medi ... strategy and financial results at the Sixth Annual JMP Securities ... 2011 at The St. Regis Hotel in New York. ...
... Reportlinker.com announces that a new market research report is ... The Global Market http://www.reportlinker.com/p0619259/Generic-Drugs-The-Global-Market.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Generic_Drug ... The global generics market is estimated at about $225 ... the value of the total global generics sector will ...
Cached Medicine Technology:Uroplasty to Present at the 6th Annual JMP Securities Healthcare Conference 2Generic Drugs: The Global Market 2Generic Drugs: The Global Market 3Generic Drugs: The Global Market 4Generic Drugs: The Global Market 5Generic Drugs: The Global Market 6Generic Drugs: The Global Market 7Generic Drugs: The Global Market 8Generic Drugs: The Global Market 9Generic Drugs: The Global Market 10Generic Drugs: The Global Market 11Generic Drugs: The Global Market 12
(Date:10/25/2014)... 2014 Background: , In 1998 Bob ... is a pioneer in the field of establishing recovery community ... treatment system and when he retired, he set out to ... public service. , 1. Where are the ... them? , 2. Can the recovery community be organized ...
(Date:10/25/2014)... October 25, 2014 QueenBeeTickets.com has a ... great selection at affordable prices. Bob Seger & The ... Center and Nationwide Arena are going on sale October ... Click Here to browse the selection of tickets ... QueenBeeTickets.com. , The famous singer is touring North America ...
(Date:10/25/2014)... CT (PRWEB) October 25, 2014 Limbkeepers® ... upcoming episode of Innovations with Ed Begley Jr, airing ... times TBA. , In this episode, Innovations will focus ... helping to protect fragile, thinning skin on arms, hands, ... will learn about these versatile products, which help reduce ...
(Date:10/25/2014)... 24, 2014 (HealthDay News) -- Researchers who discovered ... findings are cause for concern. The use ... raised for human consumption contribute to the development ... to background information from the study. Each ... about 2 million people and kill about 23,000, ...
(Date:10/25/2014)... (HealthDay News) -- October,s shorter, darker days can trigger ... according to an expert. People affected by ... tired, lack motivation and even have trouble getting out ... suicide, said Dr. Angelos Halaris, a professor in the ... Chicago Stitch School of Medicine. "Seasonal affective disorder ...
Breaking Medicine News(10 mins):Health News:CCAR Accepting Nominations for the Bob Savage Recovery Advocate of the Year Award 2Health News:QueenBeeTickets.com Features Bob Seger & The Silver Bullet Band Tickets for Charleston Civic Center, Huntington Center, and Nationwide Arena at Reduced Prices 2Health News:Upcoming Episode of Innovations with Ed Begley, Jr. to Feature Limbkeepers® 2Health News:Researchers Say Antibiotics in Fish a Health Concern 2Health News:Dark Days Here for Folks With Seasonal Depression 2
... ... ‘Advancing the Art and Science of Endometriosis: Stem Cells to Radical Excision Surgery’. ... ... of laser, light-based and radiofrequency devices for surgical, aesthetic, and ophthalmic applications, announced ...
... fewer attacks per year, save millions in health costs, ... If all states banned smoking in restaurants, offices and ... from heart attacks would drop by more than 18,000 ... bans have been implemented in some states, but not ...
... explanation for the difference, study says , THURSDAY, May ... common form of stroke has decreased significantly among whites ... new regional survey designed to be representative of the ... Greater Cincinnati/Northern Kentucky Stroke Study showed an overall drop ...
... from The University of Texas MD Anderson Children,s Cancer Hospital ... patients increased the survival of children with rare tumors in ... issue of the Journal of Pediatric Surgery , looked ... aggressive pediatric cancer known as desmoplastic small round cell tumor ...
... Montreal, May 20, 2010 The results of a ... by Dr. Jean-Claude Tardif are now available in the journal ... of the MHI Research Centre, as well as a professor in ... at the Universit de Montral. The promising findings of ...
... ... Association (NRPA) is reminding Americans to take the proper steps to ensure that their local ... Dirty Dozen, a comprehensive brochure and playground-safety resource for playground managers, parents and caregivers. ... Ashburn, VA (Vocus) May ...
Cached Medicine News:Health News:Lumenis Announced Today it is Sponsoring the Endometriosis Foundation of America's Symposium 'Advancing the Art and Science of Endometriosis: Stem Cells to Radical Excision Surgery' 2Health News:Lumenis Announced Today it is Sponsoring the Endometriosis Foundation of America's Symposium 'Advancing the Art and Science of Endometriosis: Stem Cells to Radical Excision Surgery' 3Health News:Big Decline in Heart Attacks If All States Had Smoking Bans 2Health News:Stroke Incidence Down, But Not for Blacks 2Health News:Surgical procedure offers new option for pediatric patients with rare cancer in abdomen 2Health News:Surgical procedure offers new option for pediatric patients with rare cancer in abdomen 3Health News:Patients at high risk of recurrences of heart disease: Breakthrough in prevention 2Health News:Spring into Summer with The Dirty Dozen Guide to Playground Safety 2Health News:Spring into Summer with The Dirty Dozen Guide to Playground Safety 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: